Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).
索拉非尼
癌症
作者
Zev A. Wainberg,Neil H. Segal,Dirk Jaeger,Kyung-Hun Lee,John Marshall,Scott J. Antonia,Marcus O. Butler,Rachel E. Sanborn,John Nemunaitis,Cheryl Ann Carlson,Richard S. Finn,Xiaoping Jin,Joyce Antal,Ashok Kumar Gupta,Christophe Massard
4071Background: Durvalumab, an anti-PD-L1 mAb, has shown early and durable clinical activity with manageable safety in an ongoing Phase 1/2, multicenter, open-label study in pts with advanced solid...
JY
寻道图强
好困
lin
Singularity
Cloud
123
贰鸟
shinysparrow
坚强的广山
王十
宁少爷
夏来
完美的天空
CipherSage
菠菜
穆紫
Clover04
Liar
凤凰
皖公网安备34019202002308
